WO2006002685A1 - A method and a device for determining the hydration and/or nutrition status of a patient - Google Patents

A method and a device for determining the hydration and/or nutrition status of a patient Download PDF

Info

Publication number
WO2006002685A1
WO2006002685A1 PCT/EP2004/014544 EP2004014544W WO2006002685A1 WO 2006002685 A1 WO2006002685 A1 WO 2006002685A1 EP 2004014544 W EP2004014544 W EP 2004014544W WO 2006002685 A1 WO2006002685 A1 WO 2006002685A1
Authority
WO
WIPO (PCT)
Prior art keywords
patient
mass
water
physical properties
chemical
Prior art date
Application number
PCT/EP2004/014544
Other languages
French (fr)
Inventor
Paul Chamney
Peter Wabel
Original Assignee
Fresenius Medical Care Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fresenius Medical Care Deutschland Gmbh filed Critical Fresenius Medical Care Deutschland Gmbh
Priority to DE602004028293T priority Critical patent/DE602004028293D1/en
Priority to PL04804141T priority patent/PL1765159T3/en
Priority to KR1020067025834A priority patent/KR101130902B1/en
Priority to JP2007518463A priority patent/JP5128278B2/en
Priority to CA2566643A priority patent/CA2566643C/en
Priority to CN200480043469.8A priority patent/CN101102718B/en
Priority to AT04804141T priority patent/ATE474499T1/en
Priority to US11/630,965 priority patent/US8340754B2/en
Priority to EP04804141A priority patent/EP1765159B1/en
Publication of WO2006002685A1 publication Critical patent/WO2006002685A1/en
Priority to US13/722,629 priority patent/US20130211278A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/05Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves 
    • A61B5/053Measuring electrical impedance or conductance of a portion of the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/05Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves 
    • A61B5/053Measuring electrical impedance or conductance of a portion of the body
    • A61B5/0537Measuring body composition by impedance, e.g. tissue hydration or fat content
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/103Detecting, measuring or recording devices for testing the shape, pattern, colour, size or movement of the body or parts thereof, for diagnostic purposes
    • A61B5/107Measuring physical dimensions, e.g. size of the entire body or parts thereof
    • A61B5/1073Measuring volume, e.g. of limbs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/48Other medical applications
    • A61B5/4869Determining body composition
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/48Other medical applications
    • A61B5/4869Determining body composition
    • A61B5/4872Body fat
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/72Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7271Specific aspects of physiological measurement analysis
    • A61B5/7278Artificial waveform generation or derivation, e.g. synthesising signals from measured signals

Definitions

  • the invention relates to the field of monitoring the hydration and/or nutrition status of a patient.
  • the kidneys carry out several functions for maintaining the health of a human body. First, they control the fluid balance by separating any excess fluid from the patient blood volume. Second, they serve to purify the blood from any waste substances like urea or creatinine. Last not least they also control the levels of certain substances in the blood like electrolytes in order to ensure a healthy and necessary concentration level.
  • the dry weight (for the sake of simplicity the words "weight” and “mass” shall be used synonymously throughout this patent application document - which also is usual practise in the medical field) defines the weight of a patient that would be achieved if the kidneys were working normally. In other words this represents the optimal target weight (or fluid status) which should be achieved in order to minimise cardiovascular risk. Dry weight has always been an elusive problem in routine clinical practise due to lack of quantitative methods for its assessment. Currently the dry weight problem is approached using indirect indicators like e.g. blood pressure, echocardiography investigations and subjective information such as X-rays. Furthermore it has been particularly difficult to define a set of conditions which are universally accepted as the dry weight standard. A promising method to derive the fluid status of a patient involves the use of bioimpedance measurements.
  • a small alternating current is applied to two or more electrodes which are attached to a patient and the corresponding electric potential difference is measured.
  • the various fluid compartments of a human body contribute differently to the measured signals.
  • the use of multiple frequencies allows the water in the intracellular volume (ICV) and the extracellular volume (ECV) to be determined.
  • ICV intracellular volume
  • ECV extracellular volume
  • An example of such a device is described in the international patent application WO 92/19153. However, this document discloses no method regarding how the dry weight of the particular patient can be derived.
  • US patent 5,449,000 describes a bioimpedance system also using multiple frequencies to determine water mass in the ECV and ICV. Furthermore certain population dependent data are taken for using and choosing so-called population prediction formulas. The body composition is then analysed by using these formulas and with the help of segmental bioimpedance signals.
  • the international patent application WO 02/36004 A1 describes a method and a device for deriving the dry weight of a patient with renal failure using a bioimpedance device by extrapolating an excess water volume in the extracellular volume to a condition where there would be no renal failure.
  • a mass correction term accounting for deviations within healthy human beings and being attributed to certain tissues can be derived.
  • the international patent application WO 03/053239 A1 discloses a compartmental model which addresses the variation in healthy human beings in certain body compartments in order to better separate a mal-hydration volume and other tissue components in particular with the aid of bioimpedance measurements. With such a device information on the nutrition status of a patient can also be obtained.
  • US patent 6,615,077 describes an approach for monitoring a dialysis treatment by a bioimpedance device in order to correlate the signals with the progress of the treatment.
  • a bioimpedance device in order to correlate the signals with the progress of the treatment.
  • the problem of the invention is solved by a method according to claim 1 , i.e. by a method to determine at least one of a mal-hydration component, an adipose tissue component and a lean tissue component of a patient comprising the steps of determining chemical or physical properties of the patient and deriving the at least one component on the basis of the determined chemical or physical properties of the patient and previously determined values of a mass or volume fraction of water in lean tissue and a mass or volume fraction of water in adipose tissue.
  • the invention is based on the observation that a model dividing the body of a patient into a lean tissue compartment, an adipose tissue compartment and a mal-hydration compartment is already adaquate to minimise the number of parameters involved and to still provide reliable results.
  • the inventors further recognised that it is sufficient to establish values for a water volume or mass fraction for the lean tissue on one hand and for the adipose tissue on the other hand.
  • these fractions can be taken as fixed values independent of the patient the method is applied to.
  • it is, apart from the mal- hydration water compartment, mainly the individual mixture of these two types of tissues that contributes to the differential water distribution within the patient so that it is sufficient to explicitly consider these two types of tissues for this aspect.
  • adipose tissue is considered to consist of fat cells or adipocytes suspended in extracellular fluid.
  • the adipocytes themselves consist predominantly of lipids or fat and a small quantity of intracellular fluid. Adipose tissue should therefore not be confused with fat even though they are related. Fat is simply the pure lipid whilst adipose tissue is a mixture of fat and water.
  • the adipocytes bind a proportion of extracellular fluid which makes up the total adipose tissue mass. This extracellular fluid is therefore not free fluid and must be taken into account when calculating a patient's excess fluid.
  • a device for a non-invasive, accurate and easy to use body compartment assessment comprising a measurement and/or input unit configured to provide values for chemical or physical properties of the patient to be determined, an evaluation unit configured to derive at least one component of a mal-hydration component, an adipose tissue component and a lean tissue component on the basis of the determined chemical or physical properties of the patient and previously determined values of a mass or volume fraction of water in lean tissue and a mass or volume fraction of water in adipose tissue, and a communication link between the measurement and/or input unit and the evaluation unit.
  • the evaluation unit is also configured to control the measurement and/or input unit for determining at least one of the chemical or physical properties of the patient.
  • the evaluation unit is a microprocessor unit which in turn comprises a microprocessor program storage unit, wherein in the microprocessor program storage unit a program for deriving the at least one component on the basis of the determined chemical or physical properties of the patient and previously determined values of a mass or volume fraction of water in lean tissue and a mass or volume fraction of water in adipose tissue is stored.
  • a computer program product according to claim 18 which comprises a storage medium on which a computer program is stored which is to be stored in a device according to the invention for carrying out the method according to the invention where the evaluation unit comprises a microprocessor storage unit, is also constituting a part of the invention.
  • Fig. 1a shows a schematic illustration of the three components of the body of a patient representing the mal-hydration mass MEX, the lean tissue mass MLT and the adipose tissue mass MAT,
  • Fig. 1 b shows a schematic illustration of the three components of a body of a patient according to Fig. 1a (right hand side) in relation to the mass components as derived by dual x-ray absorptiometry (DXA) (left hand side),
  • DXA dual x-ray absorptiometry
  • Fig. 2 shows a compilation of example values for the various parameters required in the example embodiments of the invention for the calculation of the body mass components
  • Fig. 3 schematically shows an embodiment of a device for the assessment of the body composition of a patient according to the present invention
  • Fig. 4 shows a bioimpedance electrode arrangement for whole body bioimpedance measurements (left hand side) and a bioimpedance electrode arrangement for segmental body bioimpedance measurements (right hand side).
  • the body of a patient can be divided into three components: an excess fluid or mal-hydration component with mass MEX, a lean tissue component with mass MLT and an adipose tissue component with mass MAT-
  • an excess fluid or mal-hydration component with mass MEX for all three components the extracellular water (ECW) and intracellular water (ICW) together with other contributions (minerals, proteins, lipids etc.) are also shown in Fig. 1 a.
  • the excess fluid MEX which mainly accumulates in the ECV space is an indicator of the mal-hydration status of a patient. In a healthy subject MEX would be vanishing.
  • MEX may also have a negative value indicating a hydration status where the patient is over hyd rated.
  • the lean and the adipose tissue are distinguished in the framework of this application by their water contents.
  • the lean tissue mass MLT comprises bones, organs (including blood) and muscles, but no lipids. More sophisticated models could be considered to include the influence of bone or other tissues, but for the present purpose such refinements are neglected.
  • Adipose tissue mass MAT is assumed to be largely comprised of lipids and water in the form of fat cells or adipocytes.
  • ECWLT and ICWLT are the volumes of extracellular and intracellular water in the lean tissue, the latter having the total mass MLT
  • ECWAT and ICWAT are the volumes of extracellular and intracellular water in the adipose tissue, the latter having the total mass MAT- Eqs. (1 ) and (2) may of course also be written in terms of fractions per tissue volume, as volume per mass or as mass per volume without leaving the concept of the invention. It is only important that the water contribution to the lean tissue on one hand and to the adipose tissue on the other hand is considered differently.
  • the fractions ⁇ LT and ⁇ AT each have a contribution ⁇ E cw from the extracellular water and a contribution ⁇ icw from the intracellular water:
  • the mass fractions as defined by some or all the Eqs. (3) to (6) are used.
  • various experimental methods may be employed. Once these values are established, as will be shown below, a set of rather simple equations may be used for routine application that can also be employed together with less sophisticated experimental methods but still lead to accurate and reliable results for the masses of the three body components M E ⁇ , M L ⁇ and MAT-
  • the lean tissue mass MLT comprises parts of the lean tissue mass MLT.DXA according to DXA and the total bone mineral content mass MJBMC-
  • the lean tissue mass MLT.DXA according to DXA also comprises the mal- hydration mass M E ⁇ and the adipose water mass.
  • compartments of a body can be probed by selecting appropriate tracer substances that dilute just in the chosen compartment.
  • Typical examples are the ECW, ICW or the total body water (TBW) volumes.
  • ECW volume of the total extracellular water of the patient
  • ICW volume of the total intracellular water of the patient
  • M whole body mass of the patient.
  • ECW ECW 11x + ECW LT + ECW AT (7)
  • ICW ICW LT + ICW AT (8)
  • TBW volume of the total body water of the patient
  • MTBMC mass of total bone mineral content of the patient
  • M whole body mass of the patient.
  • the total body water TBW can be split into three parts originating from the three components:
  • TBW ⁇ (A LT -M LT + A AT -M AT +M 11x ) (14).
  • the lean tissue mass MLT is split in this example into its water fraction and a rest fraction MMin+ P ro mainly attributing for minerals and proteins:
  • M LT A LT ⁇ M LT + M M ⁇ !+Pro (15).
  • TBW volume of the total body water of the patient
  • MLIPID lipid mass of the patient
  • M whole body mass of the patient.
  • the mass of mal-hyd ration water can be expressed as
  • TWLT is the sum of the extra- and intracellular water volumes in the lean tissue
  • TWAT is the sum of the extra- and intracellular water volumes in the adipose tissue.
  • the lipid mass MLIPID of the patient is the mass MAT of the adipose tissue without the water mass in the adipose tissue:
  • MAT may be calculated by solving Eq. (20) and MLT by solving Eq. (9):
  • M 17 M -M ⁇ -Mz x (23).
  • ECW volume of the total extracellular water of the patient
  • MLIPID lipid mass of the patient
  • M whole body mass of the patient.
  • the mass of mal-hyd ration water can be expressed as
  • M AT and MLT may be derived similar as in Example 3, i.e. according to Eqs. (22) and (23).
  • Example 5
  • ECW volume of the total extracellular water of the patient
  • ICV volume of the total intracellular cells of the patient
  • M whole body mass of the patient.
  • Example 2 has similarities with Example 1. However, instead of the ICW the intracellular volume ICV as a whole, including the volume of matter not being water is determined. In this case it is useful to introduce further constants that are related to the water mass fractions as defined by Eqs. (3) to (6).
  • the mal-hydration mass MEX has to be calculated.
  • the starting point is again the observation that this component manifests itself entirely in the ECV space, i.e. the mal-hydration water volume can be derived as ECWEX by solving Eq. (7).
  • ECW LT A E CW,LT ⁇ ⁇ CW,LT (28)
  • the chemical or physical properties that have to be determined of the patient may vary from one example to another. It is yet in all examples possible to determine at least one of a mal-hydration component, an adipose tissue component and a lean tissue component of the patient on the basis of the determined chemical or physical properties and previously determined values of a mass or volume fraction of water in lean tissue and a mass or volume fraction of water in adipose tissue.
  • the general concept of the present invention is therefore not limited to specific methods where specific properties of a patient have to be determined.
  • the key element of the invention to derive the at least one body component is to make appropriate use of the previous determined values of a mass or volume fraction of water in lean tissue and a mass or volume fraction of water in adipose tissue. The same applies not just to the method but also to any device according to the invention.
  • the device 10 comprises an evaluation unit that consists of a microprocessor unit 1 which in turn comprises a microprocessor program storage unit 1a.
  • the microprocessor unit 1 is connected to an interface unit 2 and a computer storage unit 3.
  • a program for determining the masses MEX, MLT and/or MAT of a patient is stored in the microprocessor program storage unit 1a.
  • This program may have been transferred beforehand to the microprocessor program storage unit 1a from a computer program product like a floppy disk, a CD-ROM, a DVD, a memory stick, a server or any other suitable storage medium on which the program was stored.
  • the device 10 comprises the necessary interface circuitry (not shown) whose design is - dependent of the type of computer program product - obvious to a person skilled in the art.
  • the microprocessor program controls the device to determine patient impedance values for two or more frequencies.
  • the device 10 comprises a bioimpedance measurement means 5 which is connected to the interface unit 2 by a communication link 6.
  • the bioimpedance measurement means 5 can be capable of automatically compensating for influences on the impedance data like contact resistances.
  • An example for such a bioimpedance measurement means 5 is a device from Xitron Technologies distributed under the trademark HydraTM and also described in WO 92/19153.
  • various electrode arrangements are possible. In Fig. 3 only two electrode elements 5a and 5b are attached to the bioimpedance measurement device 5.
  • Each of the electrode units 5a and 5b consists of a current injection electrode and a potential pick-up electrode (not shown).
  • the whole body impedance may be determined.
  • the body may be regarded as a combination of several homogenous cylinders, representing trunk, legs and arms. Average contributions of these components to the total impedance are also provided in Fig. 4, mainly resulting from the differing cross-sections of the cylinders.
  • the program stored in the microprocessor storage unit 1a initiates an impedance measurement at least two given frequencies and records the corresponding current and voltage signals, both being below critical thresholds so that the device just non- invasively probes the patient impedance without having any impact on the patient at all.
  • the device can easily be applied by the patient him- or herself without necessarily requiring medical staff.
  • the weight or whole body mass M of the patient can be entered into the device 10 via any input unit (not explicitly shown) connected to or being part of the interface unit 2 (e.g. a keyboard, touch screen etc.). This may be assisted by a weighing means 7 linked to the interface unit 2 by a communication link 8.
  • the interface unit 2 serves as an interface by which the values of the whole body mass M and any measured impedance or applied current and voltage values are directly exchanged via the communication link 4 between the computer storage unit 3, the program stored in the microprocessor program storage unit 1a, the interface 2 and the bioimpedance measurement means 5. As indicated it is also possible that any data from or to the weighing means 7 are directly transferred between the connected components via the communication links.
  • the program stored in the microprocessor storage unit 1a is now - with the help of stored previously established data - processing the stored data in order to determine any contributions of various body tissues components to the whole body mass M.
  • the ECW is determined by exploiting the fact that the electrical impedance of body tissue changes when alternating currents of different frequencies are applied to the patient via the electrodes.
  • the cell membranes behave as insulators and the applied current passes only through the ECV spaces, i.e. the ECW volume.
  • the cell membranes become more conductive and thus current passes through both the ICV and ECV spaces.
  • Measurement of the impedance over at least two frequencies, better over a range of frequencies allows the determination of both the ECW and the ICW.
  • a more refined model was developed recently by the same inventors as of the present invention in the patent application PCT/EP2004/007023 whose disclosure is hereby explicitly enclosed in the current application by reference.
  • Eqs. (10) to (13) to receive values for at least one of a mal-hydration component, a adipose tissue component and a lean tissue component, here the masses MEX, MLT and MAT of all three components, on the basis of previously determined values of a mass or volume fraction of water in lean tissue and a mass or volume fraction of water in adipose tissue.
  • results are finally completely or partially passed on to an output unit 9 which typically is a display device which displays the results to a user.
  • output unit 9 typically is a display device which displays the results to a user.
  • the compartmental results may be stored in the device to enable a trend analysis including previously derived results. It has also proved useful to smooth the data by deriving weighted average values from the latest and the previous data. For this purpose various algorithms are available in the art to reduce statistical scatter in the data. A useful improvement in the averaging procedure for the current result to be displayed was obtained by giving the latest measurement the highest weight and by decreasing the weight of other, previous measurements with increasing time that has passed since the measurements were taken.
  • the disclosed device and method according to the invention are hence able to provide for a powerful and more accurate technique for the management of the hydration status of a patient.
  • the invention is yielding useful further results which allow conclusions about the nutrition and/or training status of the patient. This is not dependent on whether the patient is really mal-hydrated or not.
  • the concept of the invention is not limited to the use of a bioimpedance measurement means on one hand and on the application of Example 1 on the other hand.
  • Example 1 it is not relevant as to how the values of the properties of the patient have been determined.
  • Examples 2, 3 and 4 provide examples of such variations of the concept of the invention.
  • bioimpedance other techniques may be applied that are suitable to reveal the separate character of the lean tissue on one hand and the adipose tissue on the other hand.
  • lipid mass MUPID or the total bone mineral content mass M T BMC DXA measurements are recalled.
  • Total body water, ICW or ECW may also be derived by dilution methods.
  • such a device comprises an input unit by which such chemical or physical property values may be entered into the device.
  • a device may also comprise at least partly the measurement means to determine the chemical or physical properties of the patient.
  • the evaluation unit also controls the measurement unit for carrying out the measurement of the chemical or physical properties of the patient in an automated manner.
  • the invention is particularly applicable for patients which undergo end stage renal failure treatments like hemodialysis, hemofiltration, hemodiafiltration or any forms of peritoneal dialysis (all these treatment modalities are summarised throughout this patent application by the terminology ,,a dialysis treatment").
  • end stage renal failure treatments like hemodialysis, hemofiltration, hemodiafiltration or any forms of peritoneal dialysis (all these treatment modalities are summarised throughout this patent application by the terminology , a dialysis treatment”).
  • a characterisation of hydration status might also be highly desirable within the intensive care setting, since highly abnormal electrolyte- and fluid conditions are frequent for such patients.
  • measurement in virtually any setting where nutrition or fitness parameters are required including home, pharmacies, medical practices, dialysis units, wards, fitness centres, etc., would be practical.

Abstract

The invention relates to the field of monitoring the hydration and/or nutrition status of a patient. According to the invention a method is provided to determine at least one of a mal-hydration component, an adipose tissue component and a lean tissue component of a patient comprising the steps of determining chemical or physical properties of the patient and deriving the at least one component on the basis of the determined chemical or physical properties of the patient and previously determined values of a mass or volume fraction of water in lean tissue and a mass or volume fraction of water in adipose tissue. The invention also relates to a device for carrying out the method according to the invention and to a computer program product to be used on such a device.

Description

Description
The invention relates to the field of monitoring the hydration and/or nutrition status of a patient.
The kidneys carry out several functions for maintaining the health of a human body. First, they control the fluid balance by separating any excess fluid from the patient blood volume. Second, they serve to purify the blood from any waste substances like urea or creatinine. Last not least they also control the levels of certain substances in the blood like electrolytes in order to ensure a healthy and necessary concentration level.
In case of renal failure ingested fluid accumulates in body tissues and the vascular system causing increased stress on the circulatory system. This surplus fluid has to be removed during a dialysis treatment by ultrafiltration of the blood. If insufficient fluid is removed the long term consequences can be severe, leading to high blood pressure and cardiac failure. Cardiac failure itself is many times more likely to occur in dialysis patients and it is thought that states of fluid overload are one of the major contributing factors. Removal of too much fluid is also dangerous since the dialysis patient becomes dehydrated and this invariably leads to hypotension.
The dry weight (for the sake of simplicity the words "weight" and "mass" shall be used synonymously throughout this patent application document - which also is usual practise in the medical field) defines the weight of a patient that would be achieved if the kidneys were working normally. In other words this represents the optimal target weight (or fluid status) which should be achieved in order to minimise cardiovascular risk. Dry weight has always been an elusive problem in routine clinical practise due to lack of quantitative methods for its assessment. Currently the dry weight problem is approached using indirect indicators like e.g. blood pressure, echocardiography investigations and subjective information such as X-rays. Furthermore it has been particularly difficult to define a set of conditions which are universally accepted as the dry weight standard. A promising method to derive the fluid status of a patient involves the use of bioimpedance measurements. A small alternating current is applied to two or more electrodes which are attached to a patient and the corresponding electric potential difference is measured. The various fluid compartments of a human body contribute differently to the measured signals. The use of multiple frequencies allows the water in the intracellular volume (ICV) and the extracellular volume (ECV) to be determined. An example of such a device is described in the international patent application WO 92/19153. However, this document discloses no method regarding how the dry weight of the particular patient can be derived.
US patent 5,449,000 describes a bioimpedance system also using multiple frequencies to determine water mass in the ECV and ICV. Furthermore certain population dependent data are taken for using and choosing so-called population prediction formulas. The body composition is then analysed by using these formulas and with the help of segmental bioimpedance signals.
The international patent application WO 02/36004 A1 describes a method and a device for deriving the dry weight of a patient with renal failure using a bioimpedance device by extrapolating an excess water volume in the extracellular volume to a condition where there would be no renal failure. By a similar procedure a mass correction term accounting for deviations within healthy human beings and being attributed to certain tissues can be derived.
The international patent application WO 03/053239 A1 discloses a compartmental model which addresses the variation in healthy human beings in certain body compartments in order to better separate a mal-hydration volume and other tissue components in particular with the aid of bioimpedance measurements. With such a device information on the nutrition status of a patient can also be obtained.
US patent 6,615,077 describes an approach for monitoring a dialysis treatment by a bioimpedance device in order to correlate the signals with the progress of the treatment. In view of the prior art there is a need for a simple method that requires only very few fundamental parameters and that nonetheless provides reliable results on the hydration, nutrition and training status of a patient at the same time. It is an object of this invention to provide such a method.
The problem of the invention is solved by a method according to claim 1 , i.e. by a method to determine at least one of a mal-hydration component, an adipose tissue component and a lean tissue component of a patient comprising the steps of determining chemical or physical properties of the patient and deriving the at least one component on the basis of the determined chemical or physical properties of the patient and previously determined values of a mass or volume fraction of water in lean tissue and a mass or volume fraction of water in adipose tissue.
The invention is based on the observation that a model dividing the body of a patient into a lean tissue compartment, an adipose tissue compartment and a mal-hydration compartment is already adaquate to minimise the number of parameters involved and to still provide reliable results. The inventors further recognised that it is sufficient to establish values for a water volume or mass fraction for the lean tissue on one hand and for the adipose tissue on the other hand. To apply the model these fractions can be taken as fixed values independent of the patient the method is applied to. According to the concept of the invention it is, apart from the mal- hydration water compartment, mainly the individual mixture of these two types of tissues that contributes to the differential water distribution within the patient so that it is sufficient to explicitly consider these two types of tissues for this aspect.
In the framework of the invention adipose tissue is considered to consist of fat cells or adipocytes suspended in extracellular fluid. The adipocytes themselves consist predominantly of lipids or fat and a small quantity of intracellular fluid. Adipose tissue should therefore not be confused with fat even though they are related. Fat is simply the pure lipid whilst adipose tissue is a mixture of fat and water. The adipocytes bind a proportion of extracellular fluid which makes up the total adipose tissue mass. This extracellular fluid is therefore not free fluid and must be taken into account when calculating a patient's excess fluid.
In the prior art two-compartment models have been known that divide the human body into a fat-free mass and a fat mass compartment (e.g.: K.J. Ellis, "Human Body Composition: In Vivo Methods", Physiological Reviews 80, 649 (2000)). In such a model the fat mass compartment only consists of fat or lipids whereas the remainder of the body, including the water, is lumped together in the fat-free mass compartment. This is different to the present invention that distinguishes between adipose tissue - including a non-vanishing water component - on one hand and lean tissue on the other hand. Though the lean tissue compartment is - apart from the mal-hydration compartment - again defined as the "remainder" of the body mass, the two tissues are further distinguished by their different water fractions.
It is also an object of the invention to provide a device for a non-invasive, accurate and easy to use body compartment assessment. The invention therefore also concerns a device according to claim 9 for carrying out the method according to the invention, i.e. a device comprising a measurement and/or input unit configured to provide values for chemical or physical properties of the patient to be determined, an evaluation unit configured to derive at least one component of a mal-hydration component, an adipose tissue component and a lean tissue component on the basis of the determined chemical or physical properties of the patient and previously determined values of a mass or volume fraction of water in lean tissue and a mass or volume fraction of water in adipose tissue, and a communication link between the measurement and/or input unit and the evaluation unit.
In a preferred embodiment the evaluation unit is also configured to control the measurement and/or input unit for determining at least one of the chemical or physical properties of the patient.
In a further preferred embodiment the evaluation unit is a microprocessor unit which in turn comprises a microprocessor program storage unit, wherein in the microprocessor program storage unit a program for deriving the at least one component on the basis of the determined chemical or physical properties of the patient and previously determined values of a mass or volume fraction of water in lean tissue and a mass or volume fraction of water in adipose tissue is stored.
A computer program product according to claim 18 which comprises a storage medium on which a computer program is stored which is to be stored in a device according to the invention for carrying out the method according to the invention where the evaluation unit comprises a microprocessor storage unit, is also constituting a part of the invention.
Various further embodiments of the invention are subject of the subclaims of the independent claims.
For an improved understanding of the invention, non-restrictive examples will be described with reference to the appended drawings in which
Fig. 1a shows a schematic illustration of the three components of the body of a patient representing the mal-hydration mass MEX, the lean tissue mass MLT and the adipose tissue mass MAT,
Fig. 1 b shows a schematic illustration of the three components of a body of a patient according to Fig. 1a (right hand side) in relation to the mass components as derived by dual x-ray absorptiometry (DXA) (left hand side),
Fig. 2 shows a compilation of example values for the various parameters required in the example embodiments of the invention for the calculation of the body mass components,
Fig. 3 schematically shows an embodiment of a device for the assessment of the body composition of a patient according to the present invention, and Fig. 4 shows a bioimpedance electrode arrangement for whole body bioimpedance measurements (left hand side) and a bioimpedance electrode arrangement for segmental body bioimpedance measurements (right hand side).
As illustrated in Fig. 1a the body of a patient can be divided into three components: an excess fluid or mal-hydration component with mass MEX, a lean tissue component with mass MLT and an adipose tissue component with mass MAT- For all three components the extracellular water (ECW) and intracellular water (ICW) together with other contributions (minerals, proteins, lipids etc.) are also shown in Fig. 1 a. The excess fluid MEX which mainly accumulates in the ECV space is an indicator of the mal-hydration status of a patient. In a healthy subject MEX would be vanishing. MEX may also have a negative value indicating a hydration status where the patient is over hyd rated.
The lean and the adipose tissue are distinguished in the framework of this application by their water contents. The lean tissue mass MLT comprises bones, organs (including blood) and muscles, but no lipids. More sophisticated models could be considered to include the influence of bone or other tissues, but for the present purpose such refinements are neglected. Adipose tissue mass MAT. on the other hand, is assumed to be largely comprised of lipids and water in the form of fat cells or adipocytes.
According to the concept of the invention it is necessary to distinguish between the mass fraction ΛLT of water in lean tissue as a first tissue and the corresponding mass fraction ΛAτ of water in adipose tissue as a second tissue:
_ D - (ECWLT + ICWLT) ALT = M 77 V h
LT
_ D - (ECWΛT + ICWAT)
AT ~ M JYl K wherein D is the density of water (D=O.99823 kg/litre at 360C; for the present purpose a single density value is considered to be sufficient, however small variations due to solutes in the different water compartments may be introduced), ECWLT and ICWLT are the volumes of extracellular and intracellular water in the lean tissue, the latter having the total mass MLT, and ECWAT and ICWAT are the volumes of extracellular and intracellular water in the adipose tissue, the latter having the total mass MAT- Eqs. (1 ) and (2) may of course also be written in terms of fractions per tissue volume, as volume per mass or as mass per volume without leaving the concept of the invention. It is only important that the water contribution to the lean tissue on one hand and to the adipose tissue on the other hand is considered differently.
The fractions ΛLT and ΛAT each have a contribution ΛEcw from the extracellular water and a contribution Λicw from the intracellular water:
Figure imgf000009_0001
_ D - ICWLT l yICW,LT — -. , \ V>
MLT
D - ECW
Λ AT
ECW1AT (5),
M AT
IVICW,AT ~ M Vυ/-
According to the concept of the present invention it is sufficient to previously determine at least values for the mass fractions ΛLT and ΛAT- In more refined embodiments of the invention the mass fractions as defined by some or all the Eqs. (3) to (6) are used. To determine such values various experimental methods may be employed. Once these values are established, as will be shown below, a set of rather simple equations may be used for routine application that can also be employed together with less sophisticated experimental methods but still lead to accurate and reliable results for the masses of the three body components MEχ, MLτ and MAT-
Using dual x-ray absorptiometry (DXA) or dilution experiments as reference data it is possible to derive the mass fractions of extracellular and intracellular water independently for the lean tissue and the adipose tissue mass components. A good review of such and other methods is given in the aforementioned article from KJ. Ellis.
In DXA the attenuation of two x-ray photons having different photon energies is compared. As a result it is possible to distinguish between fat mass MLIPID. lean tissue mass MLT.DXA according to DXA and the total bone mineral content mass MJBMC of a patient. The relation of these mass components to the components as used by the invention is shown in Fig. 1 b. It is important to note that the fat mass MUPID does only represent the adipose lipids of the adipose tissue, but not the1 adipose water. Furthermore, the lean tissue mass MLT comprises parts of the lean tissue mass MLT.DXA according to DXA and the total bone mineral content mass MJBMC- The lean tissue mass MLT.DXA according to DXA, on the other hand, also comprises the mal- hydration mass MEχ and the adipose water mass.
With the help of dilution experiments as a further reference method certain compartments of a body can be probed by selecting appropriate tracer substances that dilute just in the chosen compartment. Typical examples are the ECW, ICW or the total body water (TBW) volumes.
Taking the reference data from such experiments the mass fractions of Eqs. (1 ) to (6) can be derived by optimisation and also by analytical methods in an effort to map the observed data as closely as possible for as many individuals as possible. An example result of such a procedure is compiled in Fig. 2.
Once at least one of the water mass fractions ΛLT, ΛECW.LT or ΛICW.LT of the lean tissue mass component and at least one of the water mass fractions ΛAT. ΛECW,AT or ΛICWAT of the adipose tissue mass component have been previously determined it is now possible to derive vice versa at least one of the masses of the mal-hydration mass MEχ, the lean tissue mass MLτ and the adipose tissue mass MAτ from routine experimental measurement data of chemical or physical properties of the patient without having to use all the experimental methods that were applied to obtain the reference data. Depending on the kind of chemical or physical properties that are to be determined by the routine measurements, various modes of the invention are possible. Before an exemplary device according to the invention will be explained in detail five examples for such methods according to the invention are described:
Example 1
Chemical or physical properties of the patient to be determined:
ECW: volume of the total extracellular water of the patient, ICW: volume of the total intracellular water of the patient, M: whole body mass of the patient.
Each of these properties can be split into contributions from the three components:
ECW = ECW11x + ECW LT + ECW AT (7),
ICW = ICW LT + ICW AT (8),
M =Mιτ ±M +MEX (9).
Using Eqs. (3) to (6), Eqs. (7) to (9) can be solved for the masses of all three components:
M = D ECW - M (AECW:AT + kλKICWιAT ) I + kλP ICW ^ Q)
\i — Λ. sew, AT ~ ^l^ ICW, AT ) wherein
Figure imgf000011_0001
D - ICW - (M -MEX) - A
MLT = ICW, AT (12) and
V^ ICW, LT ^-ICW1AT )
MAT = M -MLT -MEX (13).
Example 2
Chemical or physical properties of the patient to be determined:
TBW: volume of the total body water of the patient MTBMC: mass of total bone mineral content of the patient M: whole body mass of the patient.
The total body water TBW can be split into three parts originating from the three components:
TBW =±(ALT -MLT + AAT -MAT +M11x) (14).
The lean tissue mass MLT is split in this example into its water fraction and a rest fraction MMin+Pro mainly attributing for minerals and proteins:
MLT = ALT MLT + MMώ!+Pro (15).
Taking kiBivic to be the share of the total bone mineral content mass MTBMC of MMin+Pro one has:
M- TBMC ~ ^TBMC ' M Mn+Pr o U ")
wherein a typical value of kjβivic is 0.2074. Together with the mass balance Eq. (9) the set of Eqs. (14) to (16) can be solved for the three component masses:
Figure imgf000013_0001
M1
MLT = , ,""" , (18) k TBMC V- ~ ^- LT )
and MAT is obtained by using Eq. (13).
Example 3
Chemical or physical properties of the patient to be determined:
TBW: volume of the total body water of the patient
MLIPID: lipid mass of the patient
M: whole body mass of the patient.
The mass of mal-hyd ration water can be expressed as
M^ = D(TBW -TWLT - TWAT) (19),
wherein TWLT is the sum of the extra- and intracellular water volumes in the lean tissue and TWAT is the sum of the extra- and intracellular water volumes in the adipose tissue. The lipid mass MLIPID of the patient is the mass MAT of the adipose tissue without the water mass in the adipose tissue:
MLIpiD = MAT -D - TW AT = MΛT{l- KAT) (20).
Inserting Eqs. (13) and (20) in Eq. (19) by making use of Eqs. (1) and (2) and solving for the mal-hydration water mass MEχ one obtains:
Figure imgf000014_0001
MAT may be calculated by solving Eq. (20) and MLT by solving Eq. (9):
MAT = MLIPID (22) and
AT d - Λ,r)
M17 = M -M^ -Mzx (23).
Example 4
Chemical or physical properties of the patient to be determined:
ECW: volume of the total extracellular water of the patient
MLIPID: lipid mass of the patient
M: whole body mass of the patient.
The mass of mal-hyd ration water can be expressed as
Mκx = D(ECW - ECW LT - ECW AT ) (24),
wherein the parameters are as defined in Example 1. Inserting Eqs. (13) and (22) in Eq. (24) by making use of Eqs. (2), (3) and (5) and solving for the mal-hydration water mass MEX one obtains:
Figure imgf000014_0002
MAT and MLT may be derived similar as in Example 3, i.e. according to Eqs. (22) and (23). Example 5
Chemical or physical properties of the patient to be determined:
ECW: volume of the total extracellular water of the patient ICV: volume of the total intracellular cells of the patient M: whole body mass of the patient.
This example has similarities with Example 1. However, instead of the ICW the intracellular volume ICV as a whole, including the volume of matter not being water is determined. In this case it is useful to introduce further constants that are related to the water mass fractions as defined by Eqs. (3) to (6).
In analogy to the ICW the total ICV can be split into components ICVAT for the adipose tissue and ICVLT for the lean tissue. These are linked to the masses Mi_τ of the lean tissue component and MAτ of the adipose tissue component by proportionality constants fι_τ and £"AT (example values as taken from the international patent application PCT/EP2004/007023 are fLτ = 0.620 litres/kg and ζAT = 0.987 litres/kg):
ICV = ICVLT + ICVAT = MLT ■ ζLT + MAT ζAT (26).
Substituting MAT in Eq. (26) with the help of Eq. (9) and solving the resultant equation for M|_τ, Eq. (27) is obtained:
^ ICV - ζAT(M - M11x) LT r ~ r (27). h LT h ΛT
Before the lean tissue mass MLτ can be derived, the mal-hydration mass MEX has to be calculated. The starting point is again the observation that this component manifests itself entirely in the ECV space, i.e. the mal-hydration water volume can be derived as ECWEX by solving Eq. (7). Using the following definitions for the volume of extracellular water per unit mass of lean tissue ΛECW.LT,
ECWLT = AECW,LT λ ΈCW,LT (28)
D
and for the volume of extracellular water per unit mass of adipose tissue ΛECW.AT,
Figure imgf000016_0001
and further introducing the definition
Figure imgf000016_0002
Eq. (7) can be solved with the help of Eqs. (9) and (27):
Figure imgf000016_0003
wherein DECW is the density of the extracellular water (=0.99823 kg/litre). Once the mal-hydration volume ECWEχ has been determined (and thus the mal-hydration mass MEX), the lean tissue mass MLT can be calculated from Eq. (27) and the adipose tissue mass MAT by Eq. (13).
As can be seen from all five examples, the chemical or physical properties that have to be determined of the patient may vary from one example to another. It is yet in all examples possible to determine at least one of a mal-hydration component, an adipose tissue component and a lean tissue component of the patient on the basis of the determined chemical or physical properties and previously determined values of a mass or volume fraction of water in lean tissue and a mass or volume fraction of water in adipose tissue. The general concept of the present invention is therefore not limited to specific methods where specific properties of a patient have to be determined. The key element of the invention to derive the at least one body component is to make appropriate use of the previous determined values of a mass or volume fraction of water in lean tissue and a mass or volume fraction of water in adipose tissue. The same applies not just to the method but also to any device according to the invention.
The method according to Example 1 is now used to describe an embodiment of a device according to the invention in detail (Fig. 3). The device 10 comprises an evaluation unit that consists of a microprocessor unit 1 which in turn comprises a microprocessor program storage unit 1a. By means of a communication link 4 the microprocessor unit 1 is connected to an interface unit 2 and a computer storage unit 3. A program for determining the masses MEX, MLT and/or MAT of a patient is stored in the microprocessor program storage unit 1a. This program may have been transferred beforehand to the microprocessor program storage unit 1a from a computer program product like a floppy disk, a CD-ROM, a DVD, a memory stick, a server or any other suitable storage medium on which the program was stored. In this case the device 10 comprises the necessary interface circuitry (not shown) whose design is - dependent of the type of computer program product - obvious to a person skilled in the art.
The microprocessor program controls the device to determine patient impedance values for two or more frequencies. For the corresponding measurement the device 10 comprises a bioimpedance measurement means 5 which is connected to the interface unit 2 by a communication link 6. The bioimpedance measurement means 5 can be capable of automatically compensating for influences on the impedance data like contact resistances. An example for such a bioimpedance measurement means 5 is a device from Xitron Technologies distributed under the trademark Hydra™ and also described in WO 92/19153. For the bioimpedance measurement various electrode arrangements are possible. In Fig. 3 only two electrode elements 5a and 5b are attached to the bioimpedance measurement device 5. Each of the electrode units 5a and 5b consists of a current injection electrode and a potential pick-up electrode (not shown). By applying the two electrode units 5a and 5b to the wrist and the ankle of a patient, respectively, as outlined in the left part of Fig. 4, the whole body impedance may be determined. Under this electrode configuration the body may be regarded as a combination of several homogenous cylinders, representing trunk, legs and arms. Average contributions of these components to the total impedance are also provided in Fig. 4, mainly resulting from the differing cross-sections of the cylinders.
By using additional electrodes on shoulder and hip, these cylindrical segments may be measured separately, thereby possibly increasing the accuracy of volume determinations. Such a configuration is displayed on the right hand side of Fig. 4. Additional electrode units 5a' and 5b' are attached close to the shoulder and the hip of the patient enabling a segmental approach to the body elements leg, arm and trunk.
The program stored in the microprocessor storage unit 1a initiates an impedance measurement at least two given frequencies and records the corresponding current and voltage signals, both being below critical thresholds so that the device just non- invasively probes the patient impedance without having any impact on the patient at all. The device can easily be applied by the patient him- or herself without necessarily requiring medical staff.
Returning to the embodiment shown in Fig. 3, the weight or whole body mass M of the patient can be entered into the device 10 via any input unit (not explicitly shown) connected to or being part of the interface unit 2 (e.g. a keyboard, touch screen etc.). This may be assisted by a weighing means 7 linked to the interface unit 2 by a communication link 8.
In the embodiment shown in Fig. 3 the interface unit 2 serves as an interface by which the values of the whole body mass M and any measured impedance or applied current and voltage values are directly exchanged via the communication link 4 between the computer storage unit 3, the program stored in the microprocessor program storage unit 1a, the interface 2 and the bioimpedance measurement means 5. As indicated it is also possible that any data from or to the weighing means 7 are directly transferred between the connected components via the communication links.
The program stored in the microprocessor storage unit 1a is now - with the help of stored previously established data - processing the stored data in order to determine any contributions of various body tissues components to the whole body mass M.
As outlined above the ECW is determined by exploiting the fact that the electrical impedance of body tissue changes when alternating currents of different frequencies are applied to the patient via the electrodes. At low frequencies the cell membranes behave as insulators and the applied current passes only through the ECV spaces, i.e. the ECW volume. At high frequencies the cell membranes become more conductive and thus current passes through both the ICV and ECV spaces. Measurement of the impedance over at least two frequencies, better over a range of frequencies, allows the determination of both the ECW and the ICW. In the prior art as described above such methods have been disclosed. A more refined model was developed recently by the same inventors as of the present invention in the patent application PCT/EP2004/007023 whose disclosure is hereby explicitly enclosed in the current application by reference.
Once any values for the ECW, ICW and whole body mass M as chemical or physical properties of the patient have been determined the microprocessor program applies Eqs. (10) to (13) to receive values for at least one of a mal-hydration component, a adipose tissue component and a lean tissue component, here the masses MEX, MLT and MAT of all three components, on the basis of previously determined values of a mass or volume fraction of water in lean tissue and a mass or volume fraction of water in adipose tissue.
The results are finally completely or partially passed on to an output unit 9 which typically is a display device which displays the results to a user. Further results - independent whether as an intermediate or as an additional result - might add to the informative character of the display.
The compartmental results may be stored in the device to enable a trend analysis including previously derived results. It has also proved useful to smooth the data by deriving weighted average values from the latest and the previous data. For this purpose various algorithms are available in the art to reduce statistical scatter in the data. A useful improvement in the averaging procedure for the current result to be displayed was obtained by giving the latest measurement the highest weight and by decreasing the weight of other, previous measurements with increasing time that has passed since the measurements were taken.
The disclosed device and method according to the invention are hence able to provide for a powerful and more accurate technique for the management of the hydration status of a patient. In case the weight MAT of the adipose tissue component and/or the weight MLT of the lean tissue component are also determined the invention is yielding useful further results which allow conclusions about the nutrition and/or training status of the patient. This is not dependent on whether the patient is really mal-hydrated or not.
It is important to note that the concept of the invention is not limited to the use of a bioimpedance measurement means on one hand and on the application of Example 1 on the other hand. For applying the concept of Example 1 it is not relevant as to how the values of the properties of the patient have been determined. In particular Examples 2, 3 and 4 provide examples of such variations of the concept of the invention. Instead of bioimpedance other techniques may be applied that are suitable to reveal the separate character of the lean tissue on one hand and the adipose tissue on the other hand. As example technique to determine the lipid mass MUPID or the total bone mineral content mass MTBMC DXA measurements are recalled. Total body water, ICW or ECW may also be derived by dilution methods.
In the simplest embodiment of a device according to the invention such a device comprises an input unit by which such chemical or physical property values may be entered into the device. As described above such a device may also comprise at least partly the measurement means to determine the chemical or physical properties of the patient. In such a case it is possible that the evaluation unit also controls the measurement unit for carrying out the measurement of the chemical or physical properties of the patient in an automated manner.
Hence management of any individual is possible, independent of any treatment modality. The invention is particularly applicable for patients which undergo end stage renal failure treatments like hemodialysis, hemofiltration, hemodiafiltration or any forms of peritoneal dialysis (all these treatment modalities are summarised throughout this patent application by the terminology ,,a dialysis treatment"). A characterisation of hydration status might also be highly desirable within the intensive care setting, since highly abnormal electrolyte- and fluid conditions are frequent for such patients. Furthermore, measurement in virtually any setting where nutrition or fitness parameters are required, including home, pharmacies, medical practices, dialysis units, wards, fitness centres, etc., would be practical.

Claims

Claims
1. A method to determine at least one of a mal-hydration component, an adipose tissue component and a lean tissue component of a patient comprising the steps of:
determining chemical or physical properties of the patient and
deriving the at least one component on the basis of the determined chemical or physical properties and previously determined values of a mass or volume fraction of water in lean tissue and a mass or volume fraction of water in adipose tissue.
2. The method according to claim 1 characterised in that the at least one component is the mass of that component of the patient.
3. The method according to claim 1 characterised in that the at least one component is the volume of that component of the patient.
4. The method according to any of the preceding claims characterised in that the chemical or physical properties of the patient comprise at least one of the whole body mass, the lipid mass and the total bone mineral content mass of the patient.
5. The method according to any of the preceding claims characterised in that the chemical or physical properties of the patient comprise the volume or mass of at least one of the total water, the extracellular water and the intracellular water of the patient.
6. The method according to any of the preceding claims characterised in that the previously determined values comprise the mass or volume fraction of the total water in lean tissue and the mass or volume fraction of the total water in adipose tissue.
7. The method according to any of the claims 1 to 5 characterised in that the previously determined values comprise the mass or volume fraction of extracellular water in lean tissue and the mass or volume fraction of extracellular water in adipose tissue.
8. The method according to any of the claims 1 to 5 characterised in that the previously determined values comprise the mass or volume fraction of intracellular water in lean tissue and the mass or volume fraction of intracellular water in adipose tissue.
9. A device (10) for carrying out the method according to any of the preceding claims comprising
a measurement and/or input unit (5) configured to provide values for the chemical or physical properties of the patient to be determined,
an . evaluation unit (1 ) configured to derive the at least one component on the basis of the determined properties of the patient and previously determined values of a mass or volume fraction of water in lean tissue and a mass or volume fraction of water in adipose tissue and
a communication link (4, 6) between the measurement and/or input unit (5) and the evaluation unit (1).
10. The device according to claim 9 characterised in that the evaluation unit (1 ) is also configured to control the measurement and/or input unit for determining at least one of the chemical or physical properties of the patient.
11. The device according to claim 9 characterised in that the evaluation unit is a microprocessor unit (1) which in turn comprises a microprocessor program storage unit (1a), wherein in the microprocessor program storage unit (1 a) a program for deriving the at least one component on the basis of the determined chemical or physical properties of the patient and previously determined values of a mass or volume fraction of water in lean tissue and a mass or volume fraction of water in adipose tissue is stored.
12. The device according to claim 11 characterised in that the program stored in the microprocessor storage unit (1a) also controls the measurement and/or input unit (5) for determining at least one of the chemical or physical properties of the patient.
13. The device according to any of the claims 9 to 12 characterised in that the measurement unit comprises a bioimpedance measurement means to determine at least one of the chemical or physical properties of the patient.
14. The device according to claim 13 characterised in that the at least one of the chemical or physical properties of the patient comprise at least one of the extracellular water volume, the intracellular water volume or the total body water volume of the patient.
15. The device according to any of the preceding claims characterised in that the measurement unit comprises scales to determine at least one of the chemical or physical properties of the patient.
16. The device according to claim 15 characterised in that the at least one of the chemical or physical properties is the whole body mass of the patient.
17. The device according to any of the claims 9 to 16 characterised in that it further comprises an output unit (9) linked to the evaluation unit (1) for outputting, preferably displaying, any data derived by the evaluation unit.
18.A computer program product characterised in that it comprises a storage medium on which a microprocessor program to be stored in the microprocessor program storage unit (1a) of the device (10) according to claim 11 is stored.
PCT/EP2004/014544 2004-06-29 2004-12-21 A method and a device for determining the hydration and/or nutrition status of a patient WO2006002685A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
DE602004028293T DE602004028293D1 (en) 2004-06-29 2004-12-21 METHOD AND DEVICE FOR DETERMINING THE HYDRITES
PL04804141T PL1765159T3 (en) 2004-06-29 2004-12-21 A method and a device for determining the hydration and/or nutrition status of a patient
KR1020067025834A KR101130902B1 (en) 2004-06-29 2004-12-21 A method and a device for determining the hydration and/or nutrition status of a patient
JP2007518463A JP5128278B2 (en) 2004-06-29 2004-12-21 Method and apparatus for determining hydration and / or nutritional status of a patient
CA2566643A CA2566643C (en) 2004-06-29 2004-12-21 A method and a device for determining the hydration and/or nutrition status of a patient
CN200480043469.8A CN101102718B (en) 2004-06-29 2004-12-21 The method and apparatus for determining patient's hydration and/or nutrition condition
AT04804141T ATE474499T1 (en) 2004-06-29 2004-12-21 METHOD AND DEVICE FOR DETERMINING THE HYDRATION AND/OR NUTRITIONAL STATUS OF A PATIENT
US11/630,965 US8340754B2 (en) 2004-06-29 2004-12-21 Method and a device for determining the hydration and/or nutrition status of a patient
EP04804141A EP1765159B1 (en) 2004-06-29 2004-12-21 A method and a device for determining the hydration and/or nutrition status of a patient
US13/722,629 US20130211278A1 (en) 2004-06-29 2012-12-20 Method and a device for determining the hydration and/or nutrition status of a patient

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2004/007023 WO2006002656A1 (en) 2004-06-29 2004-06-29 A method and a device for determining the hydration and/or nutrition status of a patient
EPPCT/EP04/007023 2004-06-29

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/722,629 Continuation US20130211278A1 (en) 2004-06-29 2012-12-20 Method and a device for determining the hydration and/or nutrition status of a patient

Publications (1)

Publication Number Publication Date
WO2006002685A1 true WO2006002685A1 (en) 2006-01-12

Family

ID=34958009

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2004/007023 WO2006002656A1 (en) 2004-06-29 2004-06-29 A method and a device for determining the hydration and/or nutrition status of a patient
PCT/EP2004/014544 WO2006002685A1 (en) 2004-06-29 2004-12-21 A method and a device for determining the hydration and/or nutrition status of a patient

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/007023 WO2006002656A1 (en) 2004-06-29 2004-06-29 A method and a device for determining the hydration and/or nutrition status of a patient

Country Status (12)

Country Link
US (3) US7917202B2 (en)
EP (2) EP1763316B1 (en)
JP (2) JP4606459B2 (en)
KR (2) KR101052679B1 (en)
CN (3) CN1960672B (en)
AT (2) ATE519424T1 (en)
CA (2) CA2562875C (en)
DE (1) DE602004028293D1 (en)
ES (2) ES2396906T3 (en)
HK (1) HK1171935A1 (en)
PL (2) PL1763316T3 (en)
WO (2) WO2006002656A1 (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008051347A1 (en) 2008-10-15 2010-04-22 Fresenius Medical Care Deutschland Gmbh Method for determining a corrected volume compartment of an amputee, apparatus for carrying out the method and computer program product
EP2295097A1 (en) 2009-09-09 2011-03-16 Fresenius Medical Care Deutschland GmbH Method and apparatus for evaluating values representing a mass or a concentration of a substance present within the body of a patient
WO2011047859A1 (en) 2009-10-22 2011-04-28 Fresenius Medical Care Deutschland Gmbh A method for assessing a patient's fluid status and/or sensitivity to fluid removal, controller, and devices
WO2011116919A1 (en) 2010-03-23 2011-09-29 Fresenius Medical Care Deutschland Gmbh Methods and apparatuses for predicting the effects of erythropoesis stimulating agents (esa), and for determining a dose to be administered
EP2380609A1 (en) 2010-04-22 2011-10-26 Fresenius Medical Care Deutschland GmbH A method for controlling of a filtration rate, controller, and devices
WO2011131319A1 (en) 2010-04-22 2011-10-27 Fresenius Medical Care Deutschland Gmbh A method for controlling of a filtration rate, controller, and devices
EP2416154A1 (en) 2010-08-03 2012-02-08 Fresenius Medical Care Deutschland GmbH Method and apparatuses for predicting the effects of erythropoesis stimulating agents (ESA), and for determining a dose to be administered
EP2469431A1 (en) 2010-12-23 2012-06-27 Fresenius Medical Care Deutschland GmbH A method for calculating or approximating a value representing the relative blood volume and devices
EP2578147A1 (en) 2011-10-07 2013-04-10 Fresenius Medical Care Deutschland GmbH Method and arrangement for determining an overhydration parameter or a body composition parameter
EP2656785A1 (en) 2012-04-26 2013-10-30 Fresenius Medical Care Deutschland GmbH Electrodes for a bio-impedance measuring device, and devices used during dialysis
DE102013011715A1 (en) 2013-07-15 2015-01-15 Fresenius Medical Care Deutschland Gmbh A method of controlling a blood treatment device and devices
EP2856941A1 (en) 2013-10-01 2015-04-08 Fresenius Medical Care Deutschland GmbH Methods and apparatuses for determining a patient's daily loss of iron
WO2016042078A1 (en) 2014-09-18 2016-03-24 Fresenius Medical Care Deutschland Gmbh Method and device for controlling a blood treatment device while taking into consideration patient feedback during the blood treatment and blood treatment device
WO2016151087A1 (en) 2015-03-24 2016-09-29 Fresenius Medical Care Deutschland Gmbh Method and apparatus for determining a patient's filtration rate
EP3671753A1 (en) 2018-12-19 2020-06-24 Fresenius Medical Care Deutschland GmbH Dialysis treatment modalities; method and devices
EP4248842A1 (en) 2022-03-25 2023-09-27 Fresenius Medical Care Deutschland GmbH Personalized patient hydration state measuring device

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7801598B2 (en) * 2000-08-14 2010-09-21 Fresenius Medical Care Holdings, Inc. Device and method for the determination of dry weight by continuous measurement of resistance and calculation of circumference in a body segment using segmental bioimpedance analysis
US7657292B2 (en) * 2001-03-16 2010-02-02 Nellcor Puritan Bennett Llc Method for evaluating extracellular water concentration in tissue
KR101052679B1 (en) 2004-06-29 2011-07-28 프레제니우스 메디칼 케어 도이칠란드 게엠베하 Methods and apparatus for measuring hydration and / or nutrition of a patient
EP3287073A1 (en) 2005-07-01 2018-02-28 Impedimed Limited Monitoring system
JP5208749B2 (en) 2005-10-11 2013-06-12 インペダイムド・リミテッド Hydration status monitoring
CA2684324C (en) 2007-04-20 2017-05-30 Impedimed Limited Monitoring system and probe
US20100234754A1 (en) * 2009-03-11 2010-09-16 Latman Neal S Method and apparatus for measuring the state of hydration of hairy animals such as horses, camels, and the like
JP5643829B2 (en) 2009-10-26 2014-12-17 インぺディメッド リミテッドImpedimed Limited Method and apparatus for use in impedance measurement analysis
EP2501283B1 (en) 2009-11-18 2016-09-21 Impedimed Limited Signal distribution for patient-electrode measurements
US8380297B2 (en) * 2010-05-17 2013-02-19 John Collins System for measuring a user's percentage of body fat
US9554725B2 (en) * 2010-08-03 2017-01-31 Medtronic Monitoring, Inc. Medical device and methods of monitoring a patient with renal dysfunction
US10362968B2 (en) 2010-10-15 2019-07-30 Fresenius Medical Care Holdings, Inc. Bioimpedance circumference measurement
CA2814655C (en) 2010-10-15 2021-07-13 Fresenius Medical Care Holdings, Inc. Dry weight predictor
EP2463795A1 (en) * 2010-12-09 2012-06-13 Fresenius Medical Care Deutschland GmbH A method for calculating or approximating one or more values representing parameters of a patient and devices
WO2013039672A1 (en) * 2011-09-13 2013-03-21 Siemens Healthcare Diagnostics Inc. Patient serum/plasma sample resistivity for electrolyte result verification
DE102011118998A1 (en) * 2011-11-14 2013-05-16 Seca Ag Method and device for determining the body weight of a person
US8700121B2 (en) 2011-12-14 2014-04-15 Intersection Medical, Inc. Devices for determining the relative spatial change in subsurface resistivities across frequencies in tissue
US9536449B2 (en) 2013-05-23 2017-01-03 Medibotics Llc Smart watch and food utensil for monitoring food consumption
US9442100B2 (en) 2013-12-18 2016-09-13 Medibotics Llc Caloric intake measuring system using spectroscopic and 3D imaging analysis
US10314492B2 (en) 2013-05-23 2019-06-11 Medibotics Llc Wearable spectroscopic sensor to measure food consumption based on interaction between light and the human body
US9254099B2 (en) 2013-05-23 2016-02-09 Medibotics Llc Smart watch and food-imaging member for monitoring food consumption
US9042596B2 (en) 2012-06-14 2015-05-26 Medibotics Llc Willpower watch (TM)—a wearable food consumption monitor
CN104768457A (en) * 2012-08-15 2015-07-08 海卓迪克斯股份公司 Diagnostic device and method for sensing hydration state of mammalian subject
US9529385B2 (en) 2013-05-23 2016-12-27 Medibotics Llc Smart watch and human-to-computer interface for monitoring food consumption
ES2537351B1 (en) 2013-11-04 2015-12-03 Universidad De Sevilla Intelligent bioimpedance sensor for biomedical applications
US11363963B2 (en) 2017-04-04 2022-06-21 Borut BARICEVIC Method and device for determining the hydration, fitness and nutrition status of a human body
US11197634B2 (en) 2020-04-28 2021-12-14 Wayne C. A. Wright Geospatial bioimpedance biosurveillance tool

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0343928A2 (en) * 1988-05-24 1989-11-29 Bioanalogics Inc System for body impedance data acquisition
EP0865763A2 (en) * 1997-03-06 1998-09-23 Nte, S.A. Apparatus for measuring volumes and global and segmental corporal composition in human beings
EP1205144A1 (en) * 2000-11-06 2002-05-15 Fresenius Medical Care Deutschland GmbH A method and a device for determining the dry weight of a patient with kidney failure
WO2003030735A1 (en) * 2001-10-12 2003-04-17 Seb S.A. Apparatus for measuring body composition

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5086781A (en) * 1989-11-14 1992-02-11 Bookspan Mark A Bioelectric apparatus for monitoring body fluid compartments
US5280429A (en) 1991-04-30 1994-01-18 Xitron Technologies Method and apparatus for displaying multi-frequency bio-impedance
CN2156809Y (en) * 1993-03-05 1994-02-23 中国人民解放军北京军区后勤部军事医学研究所 Human body fat analyzer
US5807272A (en) * 1995-10-31 1998-09-15 Worcester Polytechnic Institute Impedance spectroscopy system for ischemia monitoring and detection
JP3734350B2 (en) * 1997-10-17 2006-01-11 株式会社タニタ Body fat meter and body weight scale with body fat meter
TW529930B (en) * 1999-08-27 2003-05-01 Yamato Scale Co Ltd Health condition judging/displaying device
JP2001070273A (en) * 1999-09-03 2001-03-21 Tanita Corp Method for measuring of biological electric impedance and body composition measuring device
GB0005247D0 (en) * 2000-03-03 2000-04-26 Btg Int Ltd Electrical impedance method for differentiating tissue types
JP2001321350A (en) * 2000-05-16 2001-11-20 Sekisui Chem Co Ltd Electric characteristic measuring device
US6615077B1 (en) * 2000-08-14 2003-09-02 Renal Research Institute, Llc Device and method for monitoring and controlling physiologic parameters of a dialysis patient using segmental bioimpedence
EP1455646B1 (en) * 2001-12-12 2007-06-06 Fresenius Medical Care Deutschland GmbH Determining the hydration status of a patient
AUPS194502A0 (en) * 2002-04-26 2002-05-30 Thomson, David John A support adaptor for a bearing press
JP2004255120A (en) * 2003-02-28 2004-09-16 Tanita Corp Estimating method and measuring device for body composition
JP2004329412A (en) * 2003-05-02 2004-11-25 Tanita Corp Body composition measuring instrument
JP2004344518A (en) * 2003-05-23 2004-12-09 Tanita Corp Muscle measuring device
KR101052679B1 (en) 2004-06-29 2011-07-28 프레제니우스 메디칼 케어 도이칠란드 게엠베하 Methods and apparatus for measuring hydration and / or nutrition of a patient

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0343928A2 (en) * 1988-05-24 1989-11-29 Bioanalogics Inc System for body impedance data acquisition
EP0865763A2 (en) * 1997-03-06 1998-09-23 Nte, S.A. Apparatus for measuring volumes and global and segmental corporal composition in human beings
EP1205144A1 (en) * 2000-11-06 2002-05-15 Fresenius Medical Care Deutschland GmbH A method and a device for determining the dry weight of a patient with kidney failure
WO2003030735A1 (en) * 2001-10-12 2003-04-17 Seb S.A. Apparatus for measuring body composition

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8583226B2 (en) 2008-10-15 2013-11-12 Fresenius Medical Care Deutschland Gmbh Method for determining a corrected volume compartment of an amputated patient, device for carrying out the method and computer program product
DE102008051347B4 (en) 2008-10-15 2018-12-06 Fresenius Medical Care Deutschland Gmbh Method for determining a corrected volume compartment of an amputee, apparatus for carrying out the method and computer program product
DE102008051347A1 (en) 2008-10-15 2010-04-22 Fresenius Medical Care Deutschland Gmbh Method for determining a corrected volume compartment of an amputee, apparatus for carrying out the method and computer program product
EP2295097A1 (en) 2009-09-09 2011-03-16 Fresenius Medical Care Deutschland GmbH Method and apparatus for evaluating values representing a mass or a concentration of a substance present within the body of a patient
WO2011029569A1 (en) 2009-09-09 2011-03-17 Fresenius Medical Care Deutschland Gmbh Method and apparatus for evaluating values representing a mass or a concentration of a substance present within the body of a patient
WO2011047859A1 (en) 2009-10-22 2011-04-28 Fresenius Medical Care Deutschland Gmbh A method for assessing a patient's fluid status and/or sensitivity to fluid removal, controller, and devices
EP2316334A1 (en) 2009-10-22 2011-05-04 Fresenius Medical Care Deutschland GmbH A method for assessing a patient's fluid status and /or sensitivity to fluid removal, controller, and devices
EP3545831A1 (en) 2009-10-22 2019-10-02 Fresenius Medical Care Deutschland GmbH A method for assessing a patient's fluid status and/or sensitivity to fluid removal, controller, and devices
WO2011116919A1 (en) 2010-03-23 2011-09-29 Fresenius Medical Care Deutschland Gmbh Methods and apparatuses for predicting the effects of erythropoesis stimulating agents (esa), and for determining a dose to be administered
EP2550531B1 (en) * 2010-03-23 2017-05-31 Fresenius Medical Care Deutschland GmbH Methods and apparatuses for predicting the effects of erythropoesis stimulating agents (esa), and for determining a dose to be administered
WO2011131319A1 (en) 2010-04-22 2011-10-27 Fresenius Medical Care Deutschland Gmbh A method for controlling of a filtration rate, controller, and devices
EP2380609A1 (en) 2010-04-22 2011-10-26 Fresenius Medical Care Deutschland GmbH A method for controlling of a filtration rate, controller, and devices
EP2416154A1 (en) 2010-08-03 2012-02-08 Fresenius Medical Care Deutschland GmbH Method and apparatuses for predicting the effects of erythropoesis stimulating agents (ESA), and for determining a dose to be administered
EP2469431A1 (en) 2010-12-23 2012-06-27 Fresenius Medical Care Deutschland GmbH A method for calculating or approximating a value representing the relative blood volume and devices
US11676712B2 (en) 2010-12-23 2023-06-13 Fresenius Medical Care Deutschland Gmbh Method for calculating or approximating a value representing the relative blood volume and devices
US10413237B2 (en) 2010-12-23 2019-09-17 Fresenius Medical Care Deutschland Gmbh Method for calculating or approximating a value representing the relative blood volume and devices
WO2012084224A2 (en) 2010-12-23 2012-06-28 Fresenius Medical Care Deutschland Gmbh A method for calculating or approximating a value representing the relative blood volume and devices
WO2013050170A1 (en) 2011-10-07 2013-04-11 Fresenius Medical Care Deutschland Gmbh Method and arrangement for determining an overhydration parameter or a body composition parameter
EP2578147A1 (en) 2011-10-07 2013-04-10 Fresenius Medical Care Deutschland GmbH Method and arrangement for determining an overhydration parameter or a body composition parameter
US9980663B2 (en) 2011-10-07 2018-05-29 Fresenius Medical Care Deutschland Gmbh Method and arrangement for determining an overhydration parameter or a body composition parameter
EP2656785A1 (en) 2012-04-26 2013-10-30 Fresenius Medical Care Deutschland GmbH Electrodes for a bio-impedance measuring device, and devices used during dialysis
WO2013159935A1 (en) 2012-04-26 2013-10-31 Fresenius Medical Care Deutschland Gmbh Electrodes for a blo-impedance measuring device, and devices used during dialysis
DE102013011715A1 (en) 2013-07-15 2015-01-15 Fresenius Medical Care Deutschland Gmbh A method of controlling a blood treatment device and devices
US10406272B2 (en) 2013-10-01 2019-09-10 Fresenius Medical Care Deutschland Gmbh Methods and apparatuses for determining a patient's daily loss of iron
EP2856941A1 (en) 2013-10-01 2015-04-08 Fresenius Medical Care Deutschland GmbH Methods and apparatuses for determining a patient's daily loss of iron
DE102014113462A1 (en) 2014-09-18 2016-03-24 Fresenius Medical Care Deutschland Gmbh Method and apparatus for accounting for patient feedback in blood treatment
WO2016042078A1 (en) 2014-09-18 2016-03-24 Fresenius Medical Care Deutschland Gmbh Method and device for controlling a blood treatment device while taking into consideration patient feedback during the blood treatment and blood treatment device
WO2016151087A1 (en) 2015-03-24 2016-09-29 Fresenius Medical Care Deutschland Gmbh Method and apparatus for determining a patient's filtration rate
EP3671753A1 (en) 2018-12-19 2020-06-24 Fresenius Medical Care Deutschland GmbH Dialysis treatment modalities; method and devices
WO2020127535A1 (en) 2018-12-19 2020-06-25 Fresenius Medical Care Deutschland Gmbh Dialysis treatment modalities; method and devices
EP4248842A1 (en) 2022-03-25 2023-09-27 Fresenius Medical Care Deutschland GmbH Personalized patient hydration state measuring device
WO2023180437A1 (en) 2022-03-25 2023-09-28 Fresenius Medical Care Deutschland Gmbh Personalized patient hydration state measuring device

Also Published As

Publication number Publication date
CN1960672B (en) 2010-05-12
CA2566643A1 (en) 2006-01-12
CA2562875C (en) 2014-06-17
EP1763316A1 (en) 2007-03-21
CN1960672A (en) 2007-05-09
US20130211278A1 (en) 2013-08-15
CA2566643C (en) 2017-11-07
EP1765159A1 (en) 2007-03-28
JP4606459B2 (en) 2011-01-05
CN102512166A (en) 2012-06-27
US7917202B2 (en) 2011-03-29
CN102512166B (en) 2016-03-02
CA2562875A1 (en) 2006-01-12
ATE519424T1 (en) 2011-08-15
US20080071147A1 (en) 2008-03-20
JP2008504082A (en) 2008-02-14
ATE474499T1 (en) 2010-08-15
PL1765159T3 (en) 2010-12-31
HK1171935A1 (en) 2013-04-12
WO2006002656A1 (en) 2006-01-12
US20080086058A1 (en) 2008-04-10
CN101102718B (en) 2017-09-26
ES2396906T3 (en) 2013-03-01
KR101130902B1 (en) 2012-03-28
JP5128278B2 (en) 2013-01-23
KR101052679B1 (en) 2011-07-28
CN101102718A (en) 2008-01-09
EP1765159B1 (en) 2010-07-21
US8340754B2 (en) 2012-12-25
KR20070026559A (en) 2007-03-08
JP2008504083A (en) 2008-02-14
KR20070024572A (en) 2007-03-02
EP1763316B1 (en) 2011-08-10
ES2362218T3 (en) 2011-06-29
PL1763316T3 (en) 2012-01-31
DE602004028293D1 (en) 2010-09-02

Similar Documents

Publication Publication Date Title
US8340754B2 (en) Method and a device for determining the hydration and/or nutrition status of a patient
EP1455646B1 (en) Determining the hydration status of a patient
Jaffrin et al. Body fluid volumes measurements by impedance: A review of bioimpedance spectroscopy (BIS) and bioimpedance analysis (BIA) methods
Ellis et al. Bioelectrical impedance methods in clinical research: a follow-up to the NIH Technology Assessment Conference
EP1331880B1 (en) A method and a device for determining the dry weight of a patient with kidney failure
Broers et al. Body composition in dialysis patients: a functional assessment of bioimpedance using different prediction models
Jaffrin et al. Total body water measurement by a modification of the bioimpedance spectroscopy method
US11363963B2 (en) Method and device for determining the hydration, fitness and nutrition status of a human body
Jaffrin et al. Extracellular volume measurements using bioimpedance spectroscopy-Hanai method and wrist–ankle resistance at 50 kHz

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004804141

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2566643

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020067025834

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 200480043469.8

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 11630965

Country of ref document: US

Ref document number: 2007518463

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWP Wipo information: published in national office

Ref document number: 1020067025834

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2004804141

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11630965

Country of ref document: US